P450 Inducers and Inhibitors

USMLE Step 1 trap: Assumes CYP induction is immediate rather than delayed due to required new enzyme synthesis. CYP inducers increase enzyme synthesis over days to weeks, so their effect on substrate drug levels is delayed.

P450 inducers and inhibitors are among the highest-yield pharmacology topics on USMLE Step 1, and for good reason — they explain a huge swath of dangerous drug interactions tested in clinical vignettes. The core concept is simple: some drugs increase CYP enzyme activity (inducers), and some decrease it (inhibitors). When a second drug is a substrate for that same enzyme, its levels — and therefore its effects — change predictably. The exam tests this at three levels: raw recall of which drugs are inducers vs. inhibitors, mechanistic reasoning about what happens to substrate levels, and clinical vignette interpretation where you have to recognize that an interaction is happening and predict the outcome.

What makes this topic tricky isn't the concept itself — it's the timing and the prodrug exception. Students often assume induction and inhibition work the same way in terms of onset, but they don't. Inducers require new enzyme synthesis, so their effect builds over days to weeks. Inhibitors compete directly with or bind the enzyme, so their effect is essentially immediate. Missing this distinction will get you killed on a vignette that asks what happens 'two days after starting rifampin' versus 'two days after starting fluconazole.' The other major trap is assuming CYP inhibition always raises toxicity — it does for most drugs, but for prodrugs (like codeine or clopidogrel), inhibiting the enzyme reduces conversion to the active form, which means reduced efficacy, not increased toxicity.

For USMLE Step 1, you need two lists cold: the classic inducers (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort, chronic alcohol, griseofulvin) and the classic inhibitors (azole antifungals, macrolides, cimetidine, amiodarone, grapefruit juice, acute alcohol, ritonavir). Then you need to apply them to warfarin, oral contraceptives, cyclosporine, and statins — these are the highest-yield substrate combinations the exam returns to repeatedly.

From real student decks

86%have cards covering this topic

59%have mature cards

Common misconceptions

Common mistake

Wrong: CYP inducers immediately increase enzyme activity upon administration.

Right: CYP inducers increase enzyme synthesis over days to weeks, so their effect on substrate drug levels is delayed.

CYP inducers work by upregulating transcription of CYP genes, which means the liver has to synthesize new enzyme protein before activity increases. This process takes days to weeks, not hours. So if a vignette says a patient started rifampin two days ago and asks about warfarin levels, the answer isn't 'already reduced' — the effect is still building. This delayed onset is the opposite of CYP inhibition, which is immediate.

Common mistake

Wrong: CYP inhibitors always reduce drug toxicity by lowering active drug levels.

Right: CYP inhibitors increase levels of active substrates (raising toxicity risk), but for prodrugs they reduce active metabolite formation, decreasing efficacy.

For most drugs, CYP inhibition blocks metabolism of an already-active compound, so active drug accumulates and toxicity risk rises. But prodrugs like codeine, clopidogrel, and tamoxifen require CYP metabolism to become active. When you inhibit that enzyme, you block activation — the patient gets less therapeutic effect, not more toxicity. Always ask: is this drug a prodrug? If yes, flip your reasoning.

Common mistake

Gap: Unaware that rifampin induces CYP and renders oral contraceptives ineffective

Rifampin is a potent CYP inducer that accelerates estrogen metabolism, reducing oral contraceptive efficacy and risking unintended pregnancy.

Rifampin is one of the most potent CYP inducers in clinical use, and it dramatically accelerates the hepatic metabolism of estrogen in oral contraceptives. This drops estrogen levels below the threshold needed to suppress ovulation, effectively making the OCP fail. This is a classic Step 1 vignette setup: a patient on OCPs starts rifampin for TB prophylaxis and becomes pregnant. Any time you see rifampin + OCP in the same sentence, think: contraceptive failure.

Common mistake

Wrong: CYP inhibitors, like inducers, take weeks to exert their effect.

Right: CYP inhibitors act immediately by competing with or binding the enzyme, causing rapid rises in substrate drug levels.

CYP inhibitors act by directly competing with substrate for the enzyme's active site (competitive inhibition) or by irreversibly binding it — either way, the enzyme is blocked as soon as the inhibitor is present. There is no lag time for new protein synthesis, so the rise in substrate drug levels begins with the first dose. This is fundamentally different from inducers, which require days to weeks. Getting the timing right is critical for answering 'what happens 48 hours after starting drug X' questions correctly.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know the major CYP inducers and predict how adding one will change the plasma levels and clinical effect of a co-administered substrate drug (e.g., warfarin levels falling after rifampin is started).
Know the major CYP inhibitors and predict how adding one will raise substrate drug levels — and recognize when that rise causes toxicity (e.g., statin myopathy when an azole antifungal is added).
Read a clinical vignette describing a patient on one drug who starts another, then predict what happens to efficacy or toxicity — correctly identifying whether an induction or inhibition interaction is responsible and accounting for the timing of onset.

Can you avoid these mistakes?

A patient on warfarin for atrial fibrillation is started on rifampin for latent TB. Two weeks later his INR is subtherapeutic. What is the mechanism, and why did the effect take two weeks to appear?

A patient with HIV is on ritonavir-boosted therapy and develops severe muscle pain after starting atorvastatin. Ritonavir inhibits CYP3A4. Explain why statin toxicity occurred and what you would do differently.

A patient is on clopidogrel after coronary stenting and is also started on omeprazole (a CYP2C19 inhibitor). Six months later he has a stent thrombosis. Is this because clopidogrel levels were too high or too low, and why?

A patient on oral contraceptives starts St. John's Wort for depression. Three months later she is pregnant. Is St. John's Wort a CYP inducer or inhibitor, and what was the mechanism of contraceptive failure?

P450 Inducers and Inhibitors

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics